Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
Ella Day | May 15, 2025 | News story | Research and Development | Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17 to 20 May in Edinburgh, Scotland. This follows successful outcomes of the phase 2 study of the drug, accelerating its development as a treatment.
Shahram Attarian, international coordinating principal investigator of the study, will present the findings at the upcoming meeting.
The 15-HMedIdeS-09 phase 2 study of imlifidase demonstrated that the drug is safe and well tolerated.
Taking place in centres in the UK, France and the Netherlands, it evaluated the safety, tolerability and efficacy of imlifidase in 30 adult GBS patients in combination with standard of care intravenous immunoglobulin (IVIg).
Imlifidase is an antibody-cleaving enzyme which specifically targets immunoglobulin G (igG) to inhibit a igG-mediated immune response and potentially slow the progress of GBS and its debilitating symptoms. Under the name Idefirix, the candidate is used for the desensitisation treatment of highly sensitised adult kidney transplant patients.
GBS is a rare autoimmune disease of the peripheral nervous system which progressively weakens muscles, potentially paralysing the arms and legs severely.
“There is a clear and urgent need for new and faster treatment options in GBS. This data offers meaningful insights to help improve patient care,” said Hitto Kaufmann, chief R&D officer at Hansa Biopharma.
Ella Day
15/5/25
Related Content
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 …
Study links COVID-19 and some vaccines to increased risk of rare neurological condition
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection …
